Pascale Soyeux

Université Paris Est
Creteil, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Primary Cilium Forces Neuroendocrine Shift in Prostate Cancer through YAP1 Repression and Reduced Mitochondrial Activity.

Primary Cilium Forces Neuroendocrine Shift in Prostate Cancer through YAP1 Repression and Reduced Mitochondrial Activity.

Journal: Theranostics
Published: October 13, 2025

Targeting Aggressive Prostate Carcinoma Cells with Mesothelin-CAR-T Cells.

Targeting Aggressive Prostate Carcinoma Cells with Mesothelin-CAR-T Cells.

Journal: Biomedicines
Published: April 08, 2025

Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells.

Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells.

Journal: International journal of molecular sciences
Published: December 05, 2022

Overexpression of Nucleolin and Associated Genes in Prostate Cancer.

Overexpression of Nucleolin and Associated Genes in Prostate Cancer.

Journal: International journal of molecular sciences
Published: March 14, 2022

The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer.

The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer.

Journal: British journal of cancer
Published: January 14, 2020

CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis.

CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis.

Journal: Bladder cancer (Amsterdam, Netherlands)
Published: January 01, 2019

Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.

Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: July 27, 2017

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 04, 2016

Not Available

Not Available

Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
Published: November 07, 2015

Not Available

Not Available

Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
Published: October 14, 2015

Not Available

Not Available

Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
Published: October 14, 2015

Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.

Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.

Journal: Oncotarget
Published: September 29, 2015
Showing 1-12 of 17

Last Updated: 09/26/2026